Efficacy and safety of commonly used thromboprophylaxis agents following hip and knee arthroplasty.

Aims: We investigated the efficacy and safety profile of commonly used venous thromboembolism (VTE) prophylaxis agents following hip and knee arthroplasty. Methods: A systematic search of PubMed, Embase, Cochrane Library, Web of Science, and OrthoSearch was performed. Prophylaxis agents investigated were aspirin (< 325 mg and ≥ 325 mg daily), enoxaparin, dalteparin, fondaparinux, unfractionated heparin, warfarin, rivaroxaban, apixaban, and dabigatran. The primary efficacy outcome of interest was the risk of VTE, whereas the primary safety outcomes of interest were the risk of major bleeding events (MBE) and wound complications (WC). VTE was defined as the confirmed diagnosis of any deep vein thrombosis and/or pulmonary embolism. Network meta-analysis combining direct and indirect evidence was performed. Cluster rank analysis using the surface under cumulative ranking (SUCRA) was applied to compare each intervention group, weighing safety and efficacy outcomes. Results: Of 86 studies eligible studies, cluster rank analysis showed that aspirin < 325 mg daily (SUCRA-VTE 89.3%; SUCRA-MBE 75.3%; SUCRA-WC 71.1%), enoxaparin (SUCRA-VTE 55.7%; SUCRA-MBE 49.8%; SUCRA-WC 45.2%), and dabigatran (SUCRA-VTE 44.9%; SUCRA-MBE 52.0%; SUCRA-WC 41.9%) have an overall satisfactory efficacy and safety profile. Conclusion: We recommend the use of either aspirin < 325 mg daily, enoxaparin, or dabigatran for VTE prophylaxis following hip and knee arthroplasty.

An exploratory study of acute analgesia in tibial shaft fractures: a comparison between Maori and Non-Maori.

BACKGROUND: Published research suggests Indigenous peoples are less likely to receive analgesia in acute pain settings however there is limited data on the indigenous New Zealand Maori population. The aim of this exploratory pilot study was to compare management between Maori and non-Maori for acute fracture pain in a regional trauma centre. METHODS: A retrospective review was undertaken for 120 patients with isolated tibial shaft fractures presenting at a tertiary level trauma center between 2015 and 2020. Outcome measures reflected the patient journey including type of analgesia charted pre-hospital, in the ED and on the ward. RESULTS: Out of 104 matched patients, 48 (46%) were Maori and 65% were male. Fewer Maori received pre-hospital analgesia compared with non-Maori (odds ratio 0.29, p = 0.006). Pain scores were similar on arrival to ED (6.1 ± 3.5 versus 5.4 ± 2.7, p = 0.2). Once at hospital, there were similar rates of prescribed analgesia (paracetamol, NSAIDs, synthetics, or opioids) both in ED and the ward. Time to analgesia were also similar for both groups (72 ± 71 min versus 65 ± 63 min, P > 0.9). DISCUSSION: We found differences in pre-hospital administration of analgesia between Maori and non-Maori patients with tibial shaft fractures. However once in hospital although there was a trend towards lower prescribing for Maori, there were no significant differences. Exploring the reasons underpinning this difference and the development of robust analgesic guidelines for tibial shaft fractures may help in reducing this inequity in care, particularly in the pre-hospital setting.

Development of a Prediction Model for Significant Adverse Outcome After Spine Surgery.

STUDY DESIGN: Retrospective cohort study. OBJECTIVES: Development, validation, and decision curve analysis of a novel tool (NZSpine) for modelling risk of complications within 30 days of spine surgery. METHODS: Data was gathered retrospectively from medical records of patients who underwent spine surgery at a single tertiary centre between January 2019 and December 2020 (n = 488). Postoperative adverse events were classified objectively using the Comprehensive Complication Index (CCI). The model was derived using backward stepwise logistic regression. Validation was undertaken using bootstrap resampling. Discrimination was determined by calculating the area under the receiver operating characteristic (AUC). Calibration was assessed graphically. Clinical utility of the model was assessed using decision curve analysis (DCA). Performance measures were compared to an existing tool, SpineSage. RESULTS: Overall complication rate was 34%. Modelling showed higher age, surgical invasiveness and preoperative anemia were most strongly predictive of any complication (OR = 1.03, 1.09, 2.1 respectively, P < .001), whereas the occurrence of a major complication (CCI >26) was most strongly associated with the presence of respiratory disease (OR = 2.82, P < .001). At validation, the model showed good discrimination with an AUC of .73 (.71 - .75) and excellent calibration. SpineSage had an AUC of .71, while DCA showed the novel model had greater expected benefit at all risk thresholds. CONCLUSION: NZSpine is a novel risk assessment tool for patients undergoing acute and elective spine surgery and may help inform clinicians and patients of their perioperative risk.